Our Stock of the Week is Harrow, Inc. (HROW). HROW is an eyecare pharmaceutical company that develops and markets a portfolio of branded ophthalmic products used across a range of conditions including dry eye disease, glaucoma, cataracts, and retinal disease, with its flagship product VEVYE expected to bring in over $100 million this year, or roughly 28% of total revenue.
Shares saw two large downside gaps in the first half of the year, with the first coming on March 3rd when the Q425 report showed 36% revenue growth for 2025, which failed to meet guidance, and the second on May 12th, when a Q126 revenue missed analyst estimates. In both cases, management cited heavy sales-force reinvestment behind VEVYE as well as efforts to expand two of its other products, TRIESENCE and IHEEZO. Management, however, maintained full-year guidance of $350 million to $365 million in revenue through both reports, arguing that the heavier spending has set up a stronger second half.
Technically, HROW began working its way off lows immediately after the May 12 drop, filling the second gap a few weeks ago and then regaining the 200-day moving average in mid-June amid a constructive volume pattern. Since the, HROW has spent the past few weeks in a tight range (with both Lake Street and Cantor Fitzgerald reiterating their Buy ratings, with price targets of $60 and $88, respectively) and could be building cause to work its way into that March 3rd gap. As always, we will not chase any early strength on Monday morning, but will look to aggressively trade the stock as the chart develops.
Interested in learning about how we help clients build long-term wealth and not end up being a charity to the IRS in the process? Click here to invest with RevShark, and let’s explore the how we can to make a significant impact on your results.
This post is for educational purposes only! This is not advice or a recommendation. We do not give investment advice. Do not act on this post. Do not buy, sell, or trade the stocks mentioned herein. We WILL actively trade this stock differently than discussed herein. We will sell into strength and buy or sell at any time for any reason. We will actively trade into any unusual activity. At the time of this post, principals, employees, and affiliates of Shark Investing, Inc. and/or principals, clients, employees, and affiliates of Hammerhead Financial Strategies, LLC, directly or indirectly, controlled investment and/or trading accounts containing positions in HROW at the time this was published. To accommodate the objectives of these investing and/or trading accounts, the trading in these shares will be contrary to and/or inconsistent with the information contained in this posting.
